INmune Bio Partners With Uniphar for International Access to Ebstrocel

By Public Technologies
  • INmune Bio entered a master services agreement with Uniphar to support international access, distribution and commercialization of Ebstrocel.
  • Initial plans target named-patient access in selected European countries and the Middle East and North Africa, subject to local law.
  • Ebstrocel is an allogeneic stromal cell therapy for recessive dystrophic epidermolysis bullosa.
  • The framework could expand to broader commercial distribution as country-specific regulatory approvals, pricing and reimbursement are secured.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. INmune Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610210700PRIMZONEFULLFEED9849922) on October 21, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk